Assessing the inflammation in pediatric MOGAD: Significance of CSF HMGB1 and related biomarkers
These findings suggest that NLRP3, HMGB1, and IL-6 in the CSF may be potential therapeutic targets and are at least partly involved in the pathogenesis of pediatric MOGAD. HMGB1 in the CSF may be a potential biomarker correlating with pediatric MOGAD severity. Further investigations are warranted to validate potential cytokine pathways between that NLRP3, HMGB1, and IL-6 of MOGAD.
Authors
- Jiayu Fan (ORCID: https://orcid.org/0009-0007-8138-9829)
- Xin Wang (ORCID: https://orcid.org/0000-0002-8694-1172)
- Chong Liu (ORCID: https://orcid.org/0009-0005-9610-7500)
- Weiyi Wang (ORCID: https://orcid.org/0000-0002-1947-3356)
- Huafang Yang
- Ruibin Zhao (ORCID: https://orcid.org/0000-0002-2529-3503)
- Zhang Li (ORCID: https://orcid.org/0000-0003-4649-0757)
Institutions
- Hebei Medical University (CN)
- Hospital of Hebei Province (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-02-06
- DOI
- https://doi.org/10.3389/fimmu.2025.1534172
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00